Fenofibrate superior to O3FA in treatment of hypertriglyceridemia
Posted on Mon, Feb 13, 2012
As published in Atherosclerosis, researchers at Gachon University Gil Hospital (Incheon, ROK) have reported that fenofibrate has superior lipoprotein and metabolic effects compared to omega-3 fatty acids (O3FA) in patients with hypertriglyceridemia. The study involved 50 patients each in 3 arms: placebo; O3FA (2 g qd x 2 mos); and fenofibrate (160 mg qd x 2 mos). The patients who received O3FA had a 21% decrease in triglycerides and improved flow-mediated dilation, but no change in insulin or adiponectin levels. The patients who received fenofibrate had a 29% decrease in tryglycerides, improved flow-mediated dilation, decreased fasting insulin levels, increased adiponectin levels, and improved insulin sensitivty.